Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-07-14
2002-05-28
Jarvis, William R. A. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S211080, C514S218000, C514S250000, C514S396000
Reexamination Certificate
active
06395740
ABSTRACT:
BACKGROUND OF THE INVENTION
Bone is a dynamic tissue, and homeostasis in the adult skeleton requires a balance between bone resorption and bone formation. Osteoclasts and osteoblasts play a key role in this balance, with osteoclasts initiating bone resorption and osteoblasts synthesizing and depositing new bone matrix. Imbalances in bone homeostasis are associated with such conditions as osteoporosis, Paget's disease, and hyperparathyroidism.
The activities of osteoclasts and osteoblasts are regulated by complex interactions between systemic hormones and the local production of growth factors and cytokines. Calcitonin, a peptide hormone secreted by the thyroid and thymus of mammals, plays an important role in maintaining bone homeostasis. Calcitonin inhibits bone resorption through binding and activation of a specific calcitonin receptor on osteoclasts (
The Calcitonins—Physiology and Pharmacology
, Azria (ed.), Karger, Basel, Su., 1989), with a resultant decrease in the amount of calcium released by bone into the serum. This inhibition of bone resorption has been exploited, for instance, by using calcitonin as a treatment for osteoporosis, a disease characterized by a decrease in the skeletal mass often resulting in debilitating and painful fractures. Calcitonin is also used in the treatment of Paget's disease where it provides rapid relief from bone pain, which is frequently the primary symptom associated with this disease. This analgesic effect has also been demonstrated in patients with osteoporosis or metastatic bone disease and has been reported to relieve pain associated with diabetic neuropathy, cancer, migraine and post-hysterectomy. Reduction in bone pain occurs before the reduction of bone resorption.
Salmon calcitonin has been shown to be considerably more effective in arresting bone resorption than human forms of calcitonin. Several hypotheses have been offered to explain this observation: 1) salmon calcitonin is more resistant to degradation; 2) salmon calcitonin has a lower metabolic clearance rate (MCR); and 3) salmon calcitonin may have a slightly different conformation, resulting in a higher affinity for bone receptor sites.
Despite the advantages associated with the use of salmon calcitonin in humans, there are also disadvantages. For treatment of osteoporosis, for instance, the average cost can exceed $75 a week and involve daily prophylactic administration for 5 or more years. In the United States, calcitonin must be administered by injection, and since the disease indications for this drug are not usually life threatening, patient compliance can be low.
Furthermore, resistance to calcitonin therapy may occur with long-term use. What triggers this resistance or “escape phenomenon” is unknown (see page 1093
, Principles of Bone Biology
, Bilezikian et al., (eds.) Academic Press, NY; Raisz et al.,
Am. J. Med
. 43:684-90 (1967); McLeod & Raisz,
Endocrine Res. Comm
. 8:49-59 (1981); Wener et al.,
Endocrinology
90:752-9 (1972); and Tashjian et al.,
Recent Prog. Horm. Res
. 34:285-303 (1978)). Use of calcitonin mimetics, either in place of native calcitonins or in rotation with native calcitonins, would help avoid resistance to such treatment during long-term use. In addition, some patients develop antibodies to non-human calcitonin, calcitonin mimetics would be useful for such patients.
What is needed in the art are alternative methods of inhibiting bone resorption. Surprisingly, the present invention fulfills these and other needs.
SUMMARY OF THE INVENTION
The present invention provides isolated compounds that are calcitonin mimetics. As used herein, the term “calcitonin mimetic” refers to a compound with the ability to mimic the effects generated by calcitonin's interaction with its receptor and, by such interaction, stimulate G-protein-mediated activation by adenylate cyclase. As a result, these compounds are useful in the treatment of diseases which are mediated by calcitonin. Included among the calcitonin mimetics of the present invention are piperazine derivatives in which each of the nitrogens in the piperazine ring are alkylated or acylated with substituted aryl groups.
In view of the present discoveries, the invention provides methods for the inhibition of bone resorption which is useful for the treatment of osteoporosis, Paget's disease, hyperparathyroidism, osteomalacia, periodontal defects (bone loss prevention), hypercalcemia of malignancy, idiopathic hypercalcemia of infancy and other conditions. The calcitonin mimetics can also be used to inhibit gastric secretion in the treatment of acute pancreatitis and gastrointestinal disorders, and as analgesics, in particular for bone pain. The calcitonin mimetics described herein may be used alone or in combination with other therapeutic agents.
In other aspects, the present invention provides libraries of calcitonin mimetics which are attached to a solid support, or attached to multiple solid supports. The present invention further provides methods of preparing the libraries as well as methods of screening the libraries to determine relative binding efficiencies of the attached piperazine derivatives to the calcitonin receptor.
REFERENCES:
patent: 4153794 (1979-05-01), Ishiguro et al.
patent: 4264770 (1981-04-01), Scapini et al.
patent: 4267175 (1981-05-01), Watts
patent: 4420482 (1983-12-01), Milani et al.
patent: 5250528 (1993-10-01), Oku et al.
patent: 5286728 (1994-02-01), Ferrini
patent: 5324728 (1994-06-01), Sekine et al.
patent: 5492913 (1996-02-01), Wierzbicki et al.
patent: 5932582 (1999-08-01), Young et al.
patent: 5952306 (1999-09-01), Hartman et al.
patent: 557030 (1957-10-01), None
patent: 888 139 (1981-03-01), None
patent: 0 028 031 (1981-05-01), None
patent: 0 318 235 (1989-05-01), None
patent: 0 436 734 (1991-07-01), None
patent: 0496691 (1992-07-01), None
patent: 0 617 027 (1994-09-01), None
patent: 0 733 627 (1996-09-01), None
patent: 1 031 571 (1953-06-01), None
patent: 832 436 (1960-11-01), None
patent: 823137 (1962-05-01), None
patent: 1 297 718 (1962-05-01), None
patent: 1 303 080 (1962-07-01), None
patent: 2 113 942 (1972-06-01), None
patent: 2 291 757 (1976-06-01), None
patent: 2 353 540 (1977-12-01), None
patent: 2 377 377 (1978-08-01), None
patent: 2 387 955 (1978-11-01), None
patent: 874096 (1961-08-01), None
patent: WO 90/13539 (1990-11-01), None
patent: WO 96/31536 (1996-10-01), None
Scapini et al, abstract of patent US 4,264,770-1981.*
Sekine et al, abstract of patent US 5,324,728-1994.*
Oku et al, abstract of patent US 5,250,528-1993.*
Orjales Venero et al., abstract of patnet EP0496691A1-1992.*
McLeod, James F., et al. (1981) “Comparison of Inhibition of Bond Resorption and Escape with Calcitonin and Dibutyryl 3′, 5′ Cyclic Adenosine Monophosphate”,Endocrine Research Communications, 8(1):49-59.
Wener, Jeffrey A., et al. (1972) “Escape from Inhibition of Resoprption in Cultures of Fetal Bone Treated with Calcitonin and Parathyroid Hormone”,Endocrinology, 90:752-759.
Tashjian, Armen H., et al. (1978) “Calcitonin Binding Sites in Bone: Relationships to Biological Response and Escape”,Recent Progress in Hormone Research, 34:285-303.
Mazzuli, Gian Franco, et al. (1990) “Effects of Salmon Calcitonin on the Bone Loss Induced by Ovariectomy”,Calcif Tissue Int47:209-214.
Wronski, T.J., et al. (1991) “Skeletal Effects of Calcitonin in Ovariectomized Rats”,Endocrinology129(4):2246-2250.
Lin, Herbert Y., et al. (1991) “Expression Cloning of an Adenylate Cyclase-Coupled Calcitonin Receptor”,Science, 254:1022-1024.
Alvarez, Robert, et al. (1990) “A Single Column Method for the Assay of Adenylate Cyclase”,Analytical Biochemistry, 187:98-103.
Steiner, Alton L., et al. (1972) “Radioimmunoassay for Cyclic Nucleotides”,The Journal of Biological Chemistry, 247(4): 1106-1113.
Hayashi, T., et al. (1989) “Effect of (Asu1,7) -Eel Calcitonin on the Prevention of Osteoporosis Induced by Combination of Immobilization and Ovariectomy in the Rat”,Bone, 10:25-28.
McSheehy, P.M.J., et al. (1995) “Pharmacologic Evaluation of the Calcitonin Analogue SB 205614 in Mod
Baindur Nand
Beigel Stephanie
Labroo Virender
Martinez Theresa
Mckernan Patricia A.
Jarvis William R. A.
Kim Vickie
Townsend and Townsend / and Crew LLP
ZymoGenetics Inc.
LandOfFree
Calcitonin mimetics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calcitonin mimetics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcitonin mimetics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2903574